Based on what we have been told so far a big deal with one of the existing Multiple Myeloma drug providers will be announced soon imo.
From the Bell Potter coverage it mentioned the following
"If Patrys chooses to move forward with PAT-SM6 in Multiple Myeloma based on data superior to the competition, the path to market can be fairly swift. A larger Phase IIb that may be sufficient for approval, with Phase III studies conducted post-approval
PAT-SM6 in Multiple Myeloma would be eligible for Orphan Drug status, which can often mean favourable pricing but also brings certain tax advantages"
Ann: Change in substantial holding , page-16
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1853666 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3325244 | 5 |
View Market Depth
| Last trade - 16.12pm 16/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable